CTLA4 and melanoma: It is notable that low levels of IFNGR1 (encoding IFN-Gamma) (Supplementary Fig. 4c; as measured in all the Trp53 isogenic tumours relative to the controls at endpoint), has been associated with poor response to anti-CTLA-4 therapy (ipilimumab) in melanomas [49].